A Phase 4 interventional study of Pregabalin and Lorazepam in Generalized Anxiety Disorder, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 57 sites in 16 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
This study's enrollment of 615 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Browse Generalized Anxiety Disorder studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pregabalin
Drug: Lorazepam
Drug: Pregabalin
Drug: Placebo
Pregabalin 150-300 mg given twice a day
Also known as: Lyrica
Lorazepam 3-4 mg given twice a day
Pregabalin 450-600 mg given twice a day
Also known as: Lyrica
Placebo
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Baseline, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.
Time frame: Baseline, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Last visit on treatment, Week 1 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Last visit on treatment, Week 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Number of Participants With Rebound Anxiety for Cohort 1 (Less Than 3-Month Last Visit)
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.
Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred prior to Week 9)
Number of Participants With Rebound Anxiety for Cohort 2 (3-Month Last Visit)
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.
Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Number of Participants With Rebound Anxiety for Cohort 3 (6-Month Last Visit)
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.
Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 1 (Less Than 3-Month Last Visit)
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.
Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred prior to Week 9)
Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 2 (3-Month Last Visit)
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.
Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Number of Participants With Discontinuation-Emergent Signs and Symptoms (DESS) for Cohort 3 (6-Month Last Visit)
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.
Time frame: 2 weeks post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Change From Baseline in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Baseline, Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit)
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit)
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit)
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
Time frame: Week 1, 2 post-treatment discontinuation (discontinuation occurred after Week 15 to Week 24)
Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 1 and 2
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 1 and 2
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.
Time frame: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Change From Last Visit of Treatment in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 1 and 2
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Last visit on treatment, Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit)
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Week 1, 2 post-treatment discontinuation (discontinuation occurred prior to Week 9)
Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit)
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.
Time frame: Week 1, 2 post-treatment discontinuation (discontinuation occurred from Week 9 to Week 15)
Hamilton Anxiety Scale (HAM-A) Score for Cohort 3 (6-Month Last Visit)
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Week 1, 2 post-treatment discontinuation (discontinuation [DC] occurred after Week 15 to Week 24)
Hamilton Anxiety Scale (HAM-A) Score for Period 1
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Baseline, Week 12
Hamilton Anxiety Scale (HAM-A) Score for Period 2
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Baseline, Week 24
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 12
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Baseline, Week 12
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
Time frame: Baseline, Week 24
Clinical Global Impression - Severity (CGI-S) Score for Period 1
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.
Time frame: Baseline, Week 12
Clinical Global Impression - Severity (CGI-S) Score for Period 2
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected
Time frame: Baseline, Week 24
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.
Time frame: Baseline, Week 12
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 24
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected
Time frame: Baseline, Week 24
Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 1
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.
Time frame: Week 12
Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 2
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.
Time frame: Week 24
Sheehan-Suicidality Tracking Scale (S-STS) Score
Sheehan-Suicidality Tracking Scale (S-STS): an 8-item prospective rating scale that tracked treatment-emergent suicidal ideation and behaviors. Items 1a, 2-6, 7a, and 8 were scored on a 5-point Likert scale (ranging from 0= not at all to 4=extremely). Items 1, 1b, and 7 required yes or no responses. Total score ranged from 0 to 35, higher score indicated higher suicidal tendency.
Time frame: Baseline up to Week 24
Number of Participants With Treatment-Emergent Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and Week 12, for period 1, and between Week 13 and Week 24, for period 2, that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to Week 12 (period 1), Week 13 up to Week 24 (period 2)
| Milestone | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Started | 154 | 52 | 154 | 52 | 153 | 50 |
| Completed | 121 | 39 | 112 | 38 | 114 | 39 |
| Not completed | 33 | 13 | 42 | 14 | 39 | 11 |
| Withdrew: Adverse event | 7 | 5 | 15 | 3 | 9 | 5 |
| Withdrew: Lack of efficacy | 5 | 2 | 10 | 5 | 9 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 10 | 2 | 7 | 4 | 10 | 4 |
| Withdrew: Other | 10 | 4 | 8 | 2 | 9 | 0 |
| Milestone | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Started | 121 | 39 | 112 | 38 | 114 | 39 |
| Completed | 106 | 28 | 94 | 27 | 95 | 30 |
| Not completed | 15 | 11 | 18 | 11 | 19 | 9 |
| Withdrew: Adverse event | 5 | 4 | 5 | 2 | 3 | 1 |
| Withdrew: Lack of efficacy | 2 | 1 | 2 | 5 | 5 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 | 6 | 3 | 6 | 2 |
| Withdrew: Other | 5 | 3 | 4 | 1 | 4 | 3 |
| Milestone | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Started | 106 | 28 | 94 | 27 | 95 | 30 |
| Completed | 104 | 28 | 91 | 26 | 95 | 29 |
| Not completed | 2 | 0 | 3 | 1 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 2 | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Started | 104 | 28 | 91 | 26 | 95 | 29 |
| Completed | 102 | 27 | 89 | 26 | 93 | 29 |
| Not completed | 2 | 1 | 2 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 | 0 | 0 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Baseline (n=15,19,21) | 25.8 ± 4.23 | 24.9 ± 4.15 | 24.4 ± 4.88 |
| Change at Discontinuation Week 1 (n=15,19,18) | -7.7 ± 6.75 | -5.9 ± 7.20 | -9.9 ± 10.81 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2 | -12.0 ± 7.24 | -5.9 ± 5.46 | -9.7 ± 11.08 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Baseline | 25.0 ± 5.37 | 24.7 ± 3.89 | 24.6 ± 4.76 |
| Change at Discontinuation Week 1 | -15.3 ± 7.76 | -15.3 ± 6.71 | -15.8 ± 7.92 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2 | -15.6 ± 7.42 | -14.9 ± 7.11 | -16.0 ± 7.96 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Baseline | 25.5 ± 3.85 | 24.2 ± 4.64 | 24.7 ± 3.85 | 24.9 ± 3.82 | 24.6 ± 4.36 | 24.9 ± 3.93 |
| Change at Discontinuation Week 1 | -17.6 ± 7.25 | -18.7 ± 5.36 | -18.4 ± 6.33 | -16.5 ± 7.25 | -16.2 ± 8.11 | -19.1 ± 6.69 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline in Hamilton Anxiety Scale (HAM-A) for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2 | -16.6 ± 8.53 | -19.1 ± 5.80 | -18.3 ± 7.05 | -16.0 ± 8.17 | -16.7 ± 7.52 | -18.7 ± 7.38 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Last visit on treatment (n=15,18,20) | 10.1 ± 8.72 | 16.8 ± 13.20 | 13.1 ± 10.75 |
| Change at Discontinuation Week 1 (n=15,18,18) | 0.1 ± 9.89 | -2.8 ± 7.99 | -4.2 ± 6.12 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 1 (Less Than 3-Month Last Visit) at Discontinuation Week 2 | -2.0 ± 6.39 | -2.7 ± 9.04 | -3.2 ± 6.05 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Last visit on treatment | 7.2 ± 7.32 | 6.5 ± 6.01 | 5.0 ± 3.80 |
| Change at Discontinuation Week 1 | 1.9 ± 7.29 | 1.4 ± 4.52 | 2.3 ± 6.60 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 2 (3-Month Last Visit) at Discontinuation Week 2 | 2.1 ± 6.11 | 2.0 ± 5.51 | 1.6 ± 6.33 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Last visit on treatment | 5.2 ± 5.62 | 4.9 ± 7.15 | 3.9 ± 4.14 | 6.5 ± 6.72 | 5.3 ± 6.65 | 4.7 ± 4.50 |
| Change at Discontinuation Week 1 | 1.7 ± 4.92 | 0.0 ± 2.18 | 1.1 ± 3.50 | 1.0 ± 4.37 | 3.0 ± 6.79 | -0.1 ± 3.22 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Change From Last Visit on Treatment in Physician's Withdrawal Checklist (PWC) Score for Cohort 3 (6-Month Last Visit) at Discontinuation Week 2 | 2.8 ± 5.99 | -1.0 ± 5.65 | 1.7 ± 4.78 | 1.8 ± 5.14 | 2.2 ± 6.02 | -0.1 ± 3.63 |
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.
| participants | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Number of Participants With Rebound Anxiety for Cohort 1 (Less Than 3-Month Last Visit) | 1 | 5 | 1 |
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.
| participants | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Number of Participants With Rebound Anxiety for Cohort 2 (3-Month Last Visit) | 3 | 1 | 2 |
Rebound anxiety was defined as a rapid return of the participant's original symptoms following drug discontinuation, that were worse compared to baseline. This was characterized by a HAM-A score at the Discontinuation Week 1 or Week 2 greater than or equal to the baseline value.
| participants | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Number of Participants With Rebound Anxiety for Cohort 3 (6-Month Last Visit) | 4 | 0 | 0 | 1 | 6 | 0 |
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.
| participants | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Newly developed DESS | 6 | 0 | 3 |
| Worsened DESS | 0 | 0 | 0 |
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.
| participants | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Newly developed DESS | 40 | 38 | 36 |
| Worsened DESS | 1 | 2 | 1 |
DESS adverse events, a subset of Treatment Emergent Signs and Symptoms (TESS), were defined as those spontaneously reported adverse events that developed or existed prior to but worsened during Discontinuation Week 1 and 2.
| participants | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Newly developed DESS | 78 | 5 | 35 | 17 | 50 | 7 |
| Worsened DESS | 2 | 0 | 2 | 1 | 5 | 0 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Baseline (n=14,19,21) | 13.6 ± 8.19 | 17.6 ± 10.68 | 16.4 ± 8.62 |
| Change at Discontinuation Week 1 (n=14,19,18) | -3.4 ± 11.91 | -3.3 ± 9.12 | -5.9 ± 7.43 |
| Change at Discontinuation Week 2 (n=13,15,16) | -4.7 ± 10.62 | -2.7 ± 8.20 | -5.4 ± 8.34 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Baseline (n=57,51,52) | 17.4 ± 7.81 | 17.1 ± 9.84 | 14.8 ± 7.86 |
| Change at Discontinuation Week 1 (n=57,51,49) | -8.5 ± 9.40 | -9.3 ± 9.48 | -7.6 ± 9.53 |
| Change at Discontinuation Week 2 (n=53,48,44) | -8.3 ± 9.53 | -8.7 ± 9.68 | -8.0 ± 9.70 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Baseline (n=109,30,94,29,99,30) | 17.8 ± 8.36 | 17.8 ± 7.79 | 16.1 ± 7.52 | 17.4 ± 9.28 | 16.8 ± 8.85 | 14.9 ± 7.61 |
| Change at DC Week 1 (n=109,30,94,29,99,30) | -11.0 ± 9.48 | -12.9 ± 7.89 | -11.0 ± 8.08 | -9.9 ± 10.98 | -8.7 ± 10.77 | -10.4 ± 7.58 |
| Change at DC Week 2 (n=106,29,84,26,92,30) | -9.8 ± 10.32 | -13.8 ± 8.32 | -10.8 ± 8.42 | -10.2 ± 8.56 | -9.6 ± 9.70 | -10.3 ± 7.50 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Discontinuation Week 1 (n=15,19,18) | 10.2 ± 7.97 | 14.3 ± 10.04 | 9.1 ± 9.25 |
| Discontinuation Week 2 (n=14,15,16) | 8.2 ± 6.70 | 14.1 ± 9.16 | 10.6 ± 9.39 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Discontinuation Week 1 (n=58,52,49) | 9.1 ± 6.82 | 8.0 ± 6.19 | 7.3 ± 6.69 |
| Discontinuation Week 2 (n=54,49,44) | 8.9 ± 7.28 | 8.3 ± 6.32 | 6.9 ± 6.38 |
PWC: 20 item physician rated interview measuring anxiolytic drug withdrawal-related signs and symptoms (gastrointestinal, mood, sleep, motor, somatic, perception and cognition); range 0 (not present) to 3 (severe); total score range: 0 to 60; higher score = more affected.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Discontinuation Week 1 (n=109,30,94,29,99,30) | 6.8 ± 6.56 | 4.9 ± 5.73 | 5.1 ± 4.45 | 7.4 ± 6.43 | 8.0 ± 7.45 | 4.6 ± 4.22 |
| Discontinuation Week 2 (n=106,29,84,26,93,30) | 7.9 ± 7.59 | 4.1 ± 4.17 | 5.7 ± 6.11 | 7.1 ± 8.65 | 7.1 ± 6.64 | 4.6 ± 4.67 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Last visit on treatment (n=15,18,20) | 16.1 ± 8.46 | 21.6 ± 6.18 | 16.1 ± 10.11 |
| Change at Discontinuation Week 1 (n=15,18,18) | 2.0 ± 11.45 | -2.3 ± 4.63 | -2.4 ± 3.31 |
| Change at Discontinuation Week 2 (n=14,15,16) | -2.3 ± 9.47 | -3.5 ± 5.34 | -2.2 ± 4.18 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Last visit on treatment (n=58,52,50) | 8.0 ± 6.57 | 8.5 ± 6.50 | 6.7 ± 4.29 |
| Change at Discontinuation Week 1 (n=58,52,48) | 1.7 ± 6.69 | 0.9 ± 4.03 | 2.3 ± 5.74 |
| Change at Discontinuation Week 2 (n=54,49,44) | 1.5 ± 5.55 | 1.5 ± 6.43 | 1.5 ± 5.37 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Last visit on treatment (n=109,30,93,29,100,30) | 6.3 ± 5.89 | 5.5 ± 6.12 | 5.6 ± 5.02 | 8.3 ± 6.49 | 5.6 ± 6.17 | 5.5 ± 4.66 |
| Change at DC Week 1 (n=109,30,93,28,99,30) | 1.6 ± 4.37 | -0.0 ± 2.30 | 0.7 ± 3.08 | 0.6 ± 2.69 | 3.0 ± 5.73 | 0.3 ± 3.01 |
| Change at DC Week 2 (n=107,29,84,26,94,30) | 2.5 ± 5.74 | -0.8 ± 5.33 | 1.2 ± 3.90 | 1.5 ± 5.08 | 2.2 ± 5.39 | 0.6 ± 3.76 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Discontinuation Week 1 (n=15,19,18) | 18.1 ± 7.11 | 19.0 ± 7.61 | 14.1 ± 10.31 |
| Discontinuation Week 2 (n=14,15,16) | 13.9 ± 7.33 | 18.6 ± 6.15 | 14.6 ± 10.41 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Discontinuation Week 1 (n=58,52,48) | 9.6 ± 6.38 | 9.4 ± 6.60 | 8.8 ± 5.88 |
| Discontinuation Week 2 (n=54,49,44) | 9.0 ± 6.44 | 9.9 ± 7.04 | 8.3 ± 6.48 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Discontinuation Week 1 (n=109,30,94,28,99,30) | 7.9 ± 6.34 | 5.5 ± 4.85 | 6.3 ± 5.48 | 8.4 ± 6.67 | 8.4 ± 7.07 | 7.07 ± 4.92 |
| Discontinuation Week 2 (n=107,29,84,26,94,30) | 8.9 ± 7.60 | 5.0 ± 4.32 | 6.5 ± 6.36 | 9.2 ± 8.28 | 7.9 ± 6.27 | 6.1 ± 6.00 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Baseline | 25.3 ± 4.39 | 24.9 ± 3.87 | 24.5 ± 4.39 |
| Week 12 | 8.0 ± 6.23 | 8.9 ± 7.19 | 7.9 ± 6.70 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Baseline | 25.6 ± 3.82 | 24.6 ± 4.66 | 24.8 ± 3.77 | 25.1 ± 3.92 | 24.7 ± 4.41 | 24.1 ± 4.03 |
| Week 24 | 7.0 ± 6.53 | 7.1 ± 7.09 | 6.5 ± 5.98 | 10.2 ± 7.49 | 5.7 ± 6.06 | 6.6 ± 6.33 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 12 | -17.4 ± 7.39 | -16.0 ± 7.45 | -16.7 ± 7.92 |
HAM-A measures treatment-related changes in generalized anxiety symptoms; 14 item questionnaire scored 0 (not present) to 4 (very severe); total possible range 0 to 56. Lower score indicates less affected.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24 | -18.7 ± 7.33 | -17.5 ± 6.89 | -18.2 ± 6.59 | -14.9 ± 7.85 | -19.0 ± 7.24 | -17.5 ± 8.34 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Baseline | 4.6 ± 0.68 | 4.5 ± 0.71 | 4.4 ± 0.65 |
| Week 12 | 2.3 ± 1.06 | 2.5 ± 1.17 | 2.3 ± 1.00 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Baseline | 4.7 ± 0.65 | 4.5 ± 0.69 | 4.5 ± 0.71 | 4.5 ± 0.73 | 4.4 ± 0.68 | 4.5 ± 0.56 |
| Week 24 | 2.3 ± 1.08 | 2.2 ± 1.16 | 2.1 ± 0.97 | 2.5 ± 1.24 | 1.9 ± 0.90 | 2.4 ± 0.98 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12 | -2.3 ± 1.13 | -2.1 ± 1.13 | -2.1 ± 1.17 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 24 | -2.4 ± 1.13 | -2.3 ± 1.24 | -2.4 ± 1.04 | -2.0 ± 1.27 | -2.5 ± 1.11 | -2.2 ± 1.17 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.
| units on a scale | Pregabalin High Dose | Pregabalin Low Dose | Lorazepam |
|---|---|---|---|
| Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 1 | 1.9 ± 1.13 | 1.9 ± 1.01 | 1.9 ± 1.17 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.
| units on a scale | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Clinical Global Impression - Improvement (CGI-I) Score at the End of Period 2 | 1.7 ± 0.99 | 1.9 ± 1.15 | 1.6 ± 0.75 | 2.3 ± 1.53 | 1.5 ± 0.91 | 2.0 ± 1.07 |
Sheehan-Suicidality Tracking Scale (S-STS): an 8-item prospective rating scale that tracked treatment-emergent suicidal ideation and behaviors. Items 1a, 2-6, 7a, and 8 were scored on a 5-point Likert scale (ranging from 0= not at all to 4=extremely). Items 1, 1b, and 7 required yes or no responses. Total score ranged from 0 to 35, higher score indicated higher suicidal tendency.
No measurements were reported for this outcome.
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and Week 12, for period 1, and between Week 13 and Week 24, for period 2, that were absent before treatment or that worsened relative to pretreatment state.
| participants | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Period 1 (n=154,52,154,52,153,50) | 103 | 37 | 100 | 40 | 95 | 35 |
| Period 2 (n=121,39,112,38,114,39) | 62 | 26 | 62 | 18 | 52 | 20 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin High Dose, Pregabalin High Dose | — | 2/154 (1.3%) | 110/154 (71.4%) |
| Pregabalin High Dose, Placebo | — | 0/52 (0%) | 40/52 (76.9%) |
| Pregabalin Low Dose, Pregabalin Low Dose | — | 5/154 (3.2%) | 108/154 (70.1%) |
| Pregabalin Low Dose, Placebo | — | 2/52 (3.8%) | 38/52 (73.1%) |
| Lorazepam, Lorazepam | — | 4/153 (2.6%) | 100/153 (65.4%) |
| Lorazepam, Placebo | — | 0/50 (0%) | 35/50 (70%) |
| Event | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| Abdominal herniaGastrointestinal disorders | 0/154 | 0/52 | 0/154 | 1/52 | 0/153 | 0/50 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/154 | 0/52 | 0/154 | 1/52 | 0/153 | 0/50 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/154 | 0/52 | 0/154 | 1/52 | 0/153 | 0/50 |
| KetoacidosisMetabolism and nutrition disorders | 0/154 | 0/52 | 0/154 | 1/52 | 0/153 | 0/50 |
| Myocardial infarctionCardiac disorders | 0/154 | 0/52 | 0/154 | 0/52 | 1/153 | 0/50 |
| Myocardial ischaemiaCardiac disorders | 0/154 | 0/52 | 0/154 | 0/52 | 1/153 | 0/50 |
| Food poisoningGastrointestinal disorders | 0/154 | 0/52 | 0/154 | 0/52 | 1/153 | 0/50 |
| Typhoid feverInfections and infestations | 0/154 | 0/52 | 0/154 | 0/52 | 1/153 | 0/50 |
| Generalised anxiety disorderPsychiatric disorders | 0/154 | 0/52 | 1/154 | 0/52 | 1/153 | 0/50 |
| Inguinal herniaGastrointestinal disorders | 0/154 | 0/52 | 1/154 | 0/52 | 0/153 | 0/50 |
| Event | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo |
|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 37/154 | 17/52 | 28/154 | 14/52 | 20/153 | 10/50 |
| HeadacheNervous system disorders | 38/154 | 13/52 | 36/154 | 17/52 | 33/153 | 10/50 |
| InsomniaPsychiatric disorders | 31/154 | 15/52 | 24/154 | 12/52 | 23/153 | 13/50 |
| SomnolenceNervous system disorders | 25/154 | 7/52 | 31/154 | 9/52 | 35/153 | 13/50 |
| FatigueGeneral disorders | 16/154 | 6/52 | 15/154 | 11/52 | 15/153 | 5/50 |
| NauseaGastrointestinal disorders | 17/154 | 7/52 | 12/154 | 8/52 | 18/153 | 7/50 |
| AnxietyPsychiatric disorders | 14/154 | 6/52 | 10/154 | 1/52 | 19/153 | 5/50 |
| DiarrhoeaGastrointestinal disorders | 10/154 | 3/52 | 8/154 | 5/52 | 9/153 | 1/50 |
| NasopharyngitisInfections and infestations | 13/154 | 2/52 | 7/154 | 5/52 | 8/153 | 4/50 |
| Dry mouthGastrointestinal disorders | 13/154 | 3/52 | 5/154 | 2/52 | 8/153 | 4/50 |
| Age, Customized(participants) | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo | Total |
|---|---|---|---|---|---|---|---|
| 18 to 44 years | 75 | 30 | 100 | 28 | 86 | 27 | 346 |
| 45 to 64 years | 79 | 22 | 51 | 24 | 66 | 23 | 265 |
| Greater than or equal to 65 years | 0 | 0 | 3 | 0 | 1 | 0 | 4 |
| Sex: Female, Male(Participants) | Pregabalin High Dose, Pregabalin High Dose | Pregabalin High Dose, Placebo | Pregabalin Low Dose, Pregabalin Low Dose | Pregabalin Low Dose, Placebo | Lorazepam, Lorazepam | Lorazepam, Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 89 | 30 | 101 | 32 | 95 | 27 | 374 |
| Male | 65 | 22 | 53 | 20 | 58 | 23 | 241 |
The record gives a start of May 2009, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Generalized Anxiety Disorder →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →